Expensive AstraZeneca COVID-19 Vaccine May Happen as Expert Says Manufacturer Didn't Make Much Profit

Expensive AstraZeneca COVID-19 vaccines could arrive as the giant health firm said that it now wants to make more profit from its product.

Expensive AstraZeneca COVID-19 Vaccine Could Arrive as Expert Says Manufacturer Didn't Make Much Profit
MACCLESFIELD, UNITED KINGDOM - MAY 15: Corporate logos are seen outside the Macclesfield factory of AstraZeneca on May 15, 2006, in Macclesfield, England. Anglo-Swedish drugs giant AstraZeneca has confirmed that it is to buy biotechnology firm Cambridge Antibody Technology for GBP702m. Photo by Christopher Furlong/Getty Images

One of its scientists even defended the decision of the vaccine creator, saying that it didn't make that much profit compared to other companies.

Of course, there could be some consumers who would be disappointed with AstraZeneca's price change, especially since the global COVID-19 pandemic is still ongoing.

Right now, AstraZeneca is considered the second-largest vaccine manufacturer across the world. The giant health company was able to disperse around 2 billion doses.

However, it still falls short of Sinovac, a Chinese health firm, which was able to supply more than 2.1 billion vaccines to date.

Expensive AstraZeneca COVID-19 Vaccine?

According to Gizmodo's latest report, AstraZeneca would soon make its COVID-19 vaccine pricier compared to its current cost. The U.K.-based health company announced that the majority of the medicines it would deliver before the year ends would be expensive.

Expensive AstraZeneca COVID-19 Vaccine Could Arrive as Expert Says Manufacturer Didn't Make Much Profit
A nurse fills a syringe with the AstraZeneca Covid-19 vaccine at Dobong health care center on February 26, 2021 in Seoul, South Korea. South Korea started its Covid-19 coronavirus vaccination program today with AstraZeneca's vaccine for 785,000 medical workers and those who under the age of 65 at nursing homes. Photo by Jung Yeon-Je-Pool/Getty Images

"We can only begin to say the pandemic is actually over once there is really wide, equitable, widespread access to vaccines all around the world," said Sandy Douglas, the health expert defending AstraZeneca.

He added that the giant vaccine developer hadn't made huge revenues from its medicine compared to other medical firms. But, Douglas did not disclose the names of the companies he was referring to.

While AstraZeneca's vaccine is about to become more expensive, Pfizer's COVID-19 pill would be cheaper, announced that a new licensing agreement would allow generic-drug makers to produce its product.

AstraZeneca's Vaccine Shows New Promising Performance

AstraZeneca is considered one of the most efficient COVID-19 vaccines provided in various countries across the globe.

Now, Channel News Asia reported that a new result showed that this health innovation could prevent the novel coronavirus in longer-term. You can visit this link to see more details.

In other news, some U.S. restrictions prevent people who received Sinovac, Sputnik V, and other COVID-19 vaccines from entering the country.

For more news updates about AstraZeneca and other vaccines, always keep your tabs open here at TechTimes.

This article is owned by TechTimes

Written by: Griffin Davis

ⓒ 2024 TECHTIMES.com All rights reserved. Do not reproduce without permission.
Join the Discussion
Real Time Analytics